129 related articles for article (PubMed ID: 27804235)
1. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
3. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
[TBL] [Abstract][Full Text] [Related]
4. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Spencer A; Yoon SS; Harrison SJ; Morris SR; Smith DA; Brigandi RA; Gauvin J; Kumar R; Opalinska JB; Chen C
Blood; 2014 Oct; 124(14):2190-5. PubMed ID: 25075128
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of ofatumumab (Arzerra
Chen CI; Paul H; Le LW; Wei EN; Snitzler S; Wang T; Levina O; Kakar S; Lau A; Queau M; Johnston JB; Smith DA; Trudel S
Leuk Lymphoma; 2019 Jan; 60(1):92-100. PubMed ID: 29916761
[TBL] [Abstract][Full Text] [Related]
6. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
7. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
Karri V; Lin H; Velazquez J; Batajoo A; Parekh D; Stanton W; Abhyankar H; El-Mallawany NK; Agrusa J; Eckstein O; Gulati N; Schwartz J; Woods-Swafford W; Boyd J; Saha A; Allen CE; McClain KL
Br J Haematol; 2024 May; 204(5):1882-1887. PubMed ID: 38501390
[TBL] [Abstract][Full Text] [Related]
8. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.
Wu JH; Limmer AL; Narayanan D; Doan HQ; Simonette RA; Rady PL; Tyring SK
Clin Exp Dermatol; 2021 Dec; 46(8):1551-1554. PubMed ID: 34115902
[TBL] [Abstract][Full Text] [Related]
9. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R
Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
[TBL] [Abstract][Full Text] [Related]
12. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
13. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.
Brown NA; Elenitoba-Johnson KSJ
Curr Opin Pulm Med; 2018 May; 24(3):281-286. PubMed ID: 29470255
[TBL] [Abstract][Full Text] [Related]
15. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
16. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
[TBL] [Abstract][Full Text] [Related]
17. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
19. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
20. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
